Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Amortization of Deferred Charges data on file, last reported at $844000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 21.26% year-over-year to $844000.0 in Q1 2026; TTM through Mar 2026 was $3.2 million, a 30.99% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 37.5% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $844000.0, up from $809000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for PHAT reached as high as $844000.0 in Q1 2026 and fell as low as $273000.0 in Q2 2023.
• Historically, Amortization of Deferred Charges has averaged $590411.8 across 5 years, with a median of $564000.0 in 2022.
• Across the five-year window, Amortization of Deferred Charges tumbled 76.4% in 2022 and surged 83.15% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $497000.0 in 2022, then grew by 13.88% to $566000.0 in 2023, then increased by 11.13% to $629000.0 in 2024, then increased by 28.62% to $809000.0 in 2025, then grew by 4.33% to $844000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $844000.0 in Q1 2026, $809000.0 in Q4 2025, and $775000.0 in Q3 2025.